Columbia Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Columbia Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-821	Closed	-$111K	–	221
2019 Q1	$111K	Buy	+821	New	+$102K	0.03%	210
2018 Q4	–	Sell	-995	Closed	-$138K	–	226
2018 Q3	$138K	Buy	+995	New	+$125K	0.04%	200
2017 Q1	–	Sell	-1,780	Closed	-$218K	–	217
2016 Q4	$218K	Hold	1,780	–	–	0.07%	165
2016 Q3	$218K	Hold	1,780	–	–	0.08%	169
2016 Q2	$208K	Sell	1,780 -750	-30%	-$106K	0.07%	163
2016 Q1	$352K	Hold	2,530	–	–	0.13%	132
2015 Q4	$482K	Hold	2,530	–	–	0.19%	107
2015 Q3	$396K	Hold	2,530	–	–	0.16%	124
2015 Q2	$457K	Sell	2,530 -400	-14%	-$69K	0.17%	121
2015 Q1	$508K	Hold	2,930	–	–	0.19%	123
2014 Q4	$542K	Hold	2,930	–	–	0.21%	116
2014 Q3	$486K	Sell	2,930 -500	-15%	-$82.1K	0.2%	111
2014 Q2	$536K	Hold	3,430	–	–	0.22%	108
2014 Q1	$522K	Sell	3,430 -300	-8%	-$47.7K	0.23%	100
2013 Q4	$496K	Buy	+3,730	New	+$448K	0.22%	103

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Columbia Asset Management's ALXN Position: Q2 2019 in Review

Columbia Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 821 shares — an estimated $111K sold.

Columbia Asset Management first reported a position in ALXN in Q4 2013 and held it in 15 quarters. The position peaked at $542K in Q4 2014. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

Columbia Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Columbia Asset Management sold 821 Alexion Pharmaceuticals shares in Q2 2019, an estimated $111K.
Columbia Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 15 quarters.
Columbia Asset Management's Alexion Pharmaceuticals position peaked at $542K in Q4 2014.
636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Columbia Asset Management's 13F filing for Q2 2019, filed 15 Aug 2019.